胃癌化疗耐药的分子机制
Molecular mechanisms of chemoresistance in gastric cancer.
作者信息
Shi Wen-Jia, Gao Jin-Bo
机构信息
Wen-Jia Shi, Department of Pediatric Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
出版信息
World J Gastrointest Oncol. 2016 Sep 15;8(9):673-81. doi: 10.4251/wjgo.v8.i9.673.
Abstract
Gastric cancer is the fourth most common cancer and the second leading cause of cancer deaths worldwide. Chemotherapy is one of the major treatments for gastric cancer, but drug resistance limits the effectiveness of chemotherapy, which results in treatment failure. Resistance to chemotherapy can be present intrinsically before the administration of chemotherapy or it can develop during chemotherapy. The mechanisms of chemotherapy resistance in gastric cancer are complex and multifactorial. A variety of factors have been demonstrated to be involved in chemoresistance, including the reduced intracellular concentrations of drugs, alterations in drug targets, the dysregulation of cell survival and death signaling pathways, and interactions between cancer cells and the tumor microenvironment. This review focuses on the molecular mechanisms of chemoresistance in gastric cancer and on recent studies that have sought to overcome the underlying mechanisms of chemoresistance.
摘要
胃癌是全球第四大常见癌症，也是癌症死亡的第二大主要原因。化疗是胃癌的主要治疗方法之一，但耐药性限制了化疗的效果，导致治疗失败。化疗耐药可在化疗前就固有存在，也可在化疗期间产生。胃癌化疗耐药的机制复杂且多因素。多种因素已被证明与化疗耐药有关，包括细胞内药物浓度降低、药物靶点改变、细胞存活和死亡信号通路失调以及癌细胞与肿瘤微环境之间的相互作用。本综述重点关注胃癌化疗耐药的分子机制以及近期旨在克服化疗耐药潜在机制的研究。
相似文献
1
Molecular mechanisms of chemoresistance in gastric cancer.胃癌化疗耐药的分子机制
World J Gastrointest Oncol. 2016 Sep 15;8(9):673-81. doi: 10.4251/wjgo.v8.i9.673.
2
Role of Interleukins and New Perspectives in Mechanisms of Resistance to Chemotherapy in Gastric Cancer.白细胞介素的作用及胃癌化疗耐药机制的新观点
Biomedicines. 2022 Jul 5;10(7):1600. doi: 10.3390/biomedicines10071600.
3
The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?自噬在胃癌化疗耐药中的作用：是友还是敌？
Front Cell Dev Biol. 2020 Dec 3;8:621428. doi: 10.3389/fcell.2020.621428. eCollection 2020.
4
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.微环境酸度作为肿瘤化疗耐药性的主要决定因素：质子泵抑制剂（PPIs）作为一种新的治疗方法。
Drug Resist Updat. 2015 Nov;23:69-78. doi: 10.1016/j.drup.2015.08.004. Epub 2015 Aug 22.
5
Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.化疗和放疗耐药的分子机制及其对癌症治疗的潜在影响。
MedComm (2020). 2021 Jun 10;2(3):315-340. doi: 10.1002/mco2.55. eCollection 2021 Sep.
6
Mechanisms of Resistance to Chemotherapy in Gastric Cancer.胃癌化疗耐药机制
Anticancer Agents Med Chem. 2016;16(3):318-34. doi: 10.2174/1871520615666150803125121.
7
Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity.上皮性卵巢癌肿瘤微环境中的信号传导：肿瘤异质性的挑战。
Ann Transl Med. 2020 Jul;8(14):905. doi: 10.21037/atm-2019-cm-08.
8
The Role of Lipid Metabolism in Gastric Cancer.脂质代谢在胃癌中的作用。
Front Oncol. 2022 Jun 15;12:916661. doi: 10.3389/fonc.2022.916661. eCollection 2022.
9
Molecular mechanisms for tumour resistance to chemotherapy.肿瘤对化疗耐药的分子机制。
Clin Exp Pharmacol Physiol. 2016 Aug;43(8):723-37. doi: 10.1111/1440-1681.12581.
10
A systems pharmacology analysis of major chemotherapy combination regimens used in gastric cancer treatment: predicting potential new protein targets and drugs.系统药理学分析胃癌治疗中主要化疗联合方案：预测潜在的新蛋白靶点和药物。
Curr Cancer Drug Targets. 2011 Sep;11(7):849-69. doi: 10.2174/156800911796798977.
引用本文的文献
1
Galectins as Master Regulators of Gastric Cancer Progression.半乳糖凝集素作为胃癌进展的主要调节因子
Cells. 2025 Jul 16;14(14):1090. doi: 10.3390/cells14141090.
2
Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor.使用与DNA拓扑异构酶抑制剂偶联的靶向CDH17的抗体药物偶联物克服胃肠道癌症中的多药耐药性。
Cell Rep Med. 2025 Jul 15;6(7):102213. doi: 10.1016/j.xcrm.2025.102213. Epub 2025 Jul 1.
3
Machine Learning Model for Predicting Sertraline-like Activities and Its Impact on Cancer Chemosensitization.用于预测舍曲林样活性及其对癌症化疗增敏作用的机器学习模型。
ACS Chem Neurosci. 2025 Aug 20;16(16):3138-3148. doi: 10.1021/acschemneuro.5c00165. Epub 2025 Jun 23.
4
Association study of TYMS gene expression with TYMS and ENOSF1 genetic variants in neoadjuvant chemotherapy response of gastric cancer.TYMS基因表达与TYMS和ENOSF1基因变异在胃癌新辅助化疗反应中的关联研究。
J Pathol Transl Med. 2025 Mar;59(2):105-114. doi: 10.4132/jptm.2024.11.05. Epub 2025 Feb 25.
5
Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.马拉维若/顺铂联合用药可抑制胃癌类肿瘤生长并提高小鼠存活率。
Biol Res. 2025 Jan 18;58(1):4. doi: 10.1186/s40659-024-00581-3.
6
EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.表皮生长因子受体和 PI3K 信号通路作为转移性胃腺癌患者循环肿瘤细胞的有前途的靶点。
Int J Mol Sci. 2024 May 20;25(10):5565. doi: 10.3390/ijms25105565.
7
Identification and characterization of ferroptosis-related genes in therapy-resistant gastric cancer.鉴定和特征分析治疗抵抗性胃癌中的铁死亡相关基因。
Medicine (Baltimore). 2024 May 17;103(20):e38193. doi: 10.1097/MD.0000000000038193.
8
Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.胰岛素样生长因子-1受体在吸烟相关肺癌发生中的作用
Biomedicines. 2024 Mar 2;12(3):563. doi: 10.3390/biomedicines12030563.
9
Targeting Ubiquitin-specific Protease 5 Overcomes Chemoresistance via Negatively Regulating p53 in Gastric Cancer.靶向泛素特异性蛋白酶5通过负调控胃癌中的p53克服化疗耐药性。
Curr Mol Med. 2025;25(2):211-221. doi: 10.2174/0115665240278762240202103722.
10
Role of microRNA-494 in tumor progression.微小RNA-494在肿瘤进展中的作用。
Am J Transl Res. 2023 Nov 15;15(11):6342-6361. eCollection 2023.
本文引用的文献
1
Mitochondria-Judges and Executioners of Cell Death Sentences.线粒体——细胞死亡判决的评判者与执行者
Mol Cell. 2016 Mar 3;61(5):695-704. doi: 10.1016/j.molcel.2016.02.019.
2
Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.细胞因子和血管生成因子（CAFs）的特征定义了胃癌的一个临床不同亚组。
Gastric Cancer. 2017 Jan;20(1):164-174. doi: 10.1007/s10120-015-0583-z. Epub 2015 Dec 17.
3
Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer.丝裂原活化蛋白激酶信号通路与胃癌的侵袭和转移
World J Gastroenterol. 2015 Nov 7;21(41):11673-9. doi: 10.3748/wjg.v21.i41.11673.
4
Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance.长链非编码RNA PVT1在胃癌细胞中的过表达促进多药耐药性的发展。
Biochem Biophys Res Commun. 2015 Jul 3;462(3):227-32. doi: 10.1016/j.bbrc.2015.04.121. Epub 2015 May 5.
5
IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance.白细胞介素-33诱导的JNK信号通路激活赋予胃癌化疗耐药性。
Oncol Rep. 2015 Jun;33(6):2746-52. doi: 10.3892/or.2015.3898. Epub 2015 Apr 3.
6
Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop.胃癌细胞中曲妥珠单抗耐药性的获得与IL-6/STAT3/Jagged-1/Notch正反馈回路的激活有关。
Oncotarget. 2015 Mar 10;6(7):5072-87. doi: 10.18632/oncotarget.3241.
7
Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer.多药耐药相关蛋白的表达及其与胃癌术后个体化化疗的关系
World J Surg Oncol. 2014 Oct 11;12:307. doi: 10.1186/1477-7819-12-307.
8
Inhibition of the p38 MAPK pathway sensitizes human gastric cells to doxorubicin treatment in vitro and in vivo.抑制p38丝裂原活化蛋白激酶（MAPK）通路可使人类胃细胞在体外和体内对阿霉素治疗敏感。
Mol Med Rep. 2014 Dec;10(6):3275-81. doi: 10.3892/mmr.2014.2598. Epub 2014 Sep 25.
9
Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients.ABCB1免疫组化表达与胃癌患者总生存期之间的关联。
Asian Pac J Cancer Prev. 2014;15(16):6935-8. doi: 10.7314/apjcp.2014.15.16.6935.
10
3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity.3β-乙酰 tormentic 酸通过调节细胞内谷胱甘肽水平和抑制谷胱甘肽 S-转移酶活性逆转 MRP1/ABCC1 介导的癌症耐药性。
Eur J Pharmacol. 2014 Oct 15;741:140-9. doi: 10.1016/j.ejphar.2014.07.054. Epub 2014 Aug 9.
Zotero 插件